Tags

Type your tag names separated by a space and hit enter

Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes.

Abstract

The cannabinoid receptors for Δ(9)-THC, and particularly, the CB(1) receptor, as well as its endogenous ligands, the endocannabinoids anandamide and 2-arachidonoylglycerol, are deeply involved in all aspects of the control of energy balance in mammals. While initially it was believed that this endocannabinoid signaling system would only facilitate energy intake, we now know that perhaps even more important functions of endocannabinoids and CB(1) receptors in this context are to enhance energy storage into the adipose tissue and reduce energy expenditure by influencing both lipid and glucose metabolism. Although normally well controlled by hormones and neuropeptides, both central and peripheral aspects of endocannabinoid regulation of energy balance can become dysregulated and contribute to obesity, dyslipidemia, and type 2 diabetes, thus raising the possibility that CB(1) antagonists might be used for the treatment of these metabolic disorders. On the other hand, evidence is emerging that some nonpsychotropic plant cannabinoids, such as cannabidiol, can be employed to retard β-cell damage in type 1 diabetes. These novel aspects of endocannabinoid research are reviewed in this chapter, with emphasis on the biological effects of plant cannabinoids and endocannabinoid receptor antagonists in diabetes.

Authors+Show Affiliations

Endocannabinoid Research Group, Institute of Biomolecular Chemistry, National Research Council, Via Campi Flegrei 34 Comprensorio Olivetti, 80078, Pozzuoli, NA, Italy.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

21484568

Citation

Di Marzo, Vincenzo, et al. "Cannabinoids and Endocannabinoids in Metabolic Disorders With Focus On Diabetes." Handbook of Experimental Pharmacology, 2011, pp. 75-104.
Di Marzo V, Piscitelli F, Mechoulam R. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb Exp Pharmacol. 2011.
Di Marzo, V., Piscitelli, F., & Mechoulam, R. (2011). Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handbook of Experimental Pharmacology, (203), 75-104. https://doi.org/10.1007/978-3-642-17214-4_4
Di Marzo V, Piscitelli F, Mechoulam R. Cannabinoids and Endocannabinoids in Metabolic Disorders With Focus On Diabetes. Handb Exp Pharmacol. 2011;(203)75-104. PubMed PMID: 21484568.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. AU - Di Marzo,Vincenzo, AU - Piscitelli,Fabiana, AU - Mechoulam,Raphael, PY - 2011/4/13/entrez PY - 2011/4/13/pubmed PY - 2011/5/19/medline SP - 75 EP - 104 JF - Handbook of experimental pharmacology JO - Handb Exp Pharmacol IS - 203 N2 - The cannabinoid receptors for Δ(9)-THC, and particularly, the CB(1) receptor, as well as its endogenous ligands, the endocannabinoids anandamide and 2-arachidonoylglycerol, are deeply involved in all aspects of the control of energy balance in mammals. While initially it was believed that this endocannabinoid signaling system would only facilitate energy intake, we now know that perhaps even more important functions of endocannabinoids and CB(1) receptors in this context are to enhance energy storage into the adipose tissue and reduce energy expenditure by influencing both lipid and glucose metabolism. Although normally well controlled by hormones and neuropeptides, both central and peripheral aspects of endocannabinoid regulation of energy balance can become dysregulated and contribute to obesity, dyslipidemia, and type 2 diabetes, thus raising the possibility that CB(1) antagonists might be used for the treatment of these metabolic disorders. On the other hand, evidence is emerging that some nonpsychotropic plant cannabinoids, such as cannabidiol, can be employed to retard β-cell damage in type 1 diabetes. These novel aspects of endocannabinoid research are reviewed in this chapter, with emphasis on the biological effects of plant cannabinoids and endocannabinoid receptor antagonists in diabetes. SN - 0171-2004 UR - https://www.unboundmedicine.com/medline/citation/21484568/abstract/Cannabinoids_and_Endocannabinoids_in_Metabolic_Disorders_with_Focus_on_Diabetes_ L2 - https://dx.doi.org/10.1007/978-3-642-17214-4_4 DB - PRIME DP - Unbound Medicine ER -